Hemostemix Inc. (CVE:HEM – Get Free Report) shares fell 19.4% during mid-day trading on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. 519,694 shares were traded during mid-day trading, a decline of 1% from the average session volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The company has a market cap of C$28.42 million, a P/E ratio of -5.69 and a beta of 0.20. The company’s 50-day moving average price is C$0.20 and its two-hundred day moving average price is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- How to Calculate Options Profits
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Should You Hold NVIDIA Stock for the Long Haul or Trade It?
- Why is the Ex-Dividend Date Significant to Investors?
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
